Cambrex announces further investment in US with expansion at Iowa plant

Manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), Cambrex, has revealed that it will be investing in the expansion of chemical and analytical development capabilities at its Charles City, Iowa plant in the US.

This proposed expansion plan includes the construction of an additional 2,000 sq.ft of laboratory space for development projects and will support the hiring of an additional 14 chemists. It is anticipated that the building and validation of equipment should be completed by the first quarter this year (2018).

“The Charles City site has seen multiple investments and expansions in manufacturing capacity over the past five years to meet market demand, and this in turn, has led to us needing to increase the capacity of the supporting development and analytical functions,” commented Joe Nettleton, vice president US Operations, Cambrex. “Our strategy in expanding the development capabilities across the sites at both Charles City and High Point is to ensure both facilities are harmonized and can function synergistically so that projects can be seamlessly transferred between the two.”

This expansion announcement is in parallel to the company’s investments, revealed last year (2017), at its High Point facility in North Carolina, which is expected to create up to 18 new jobs.